Overview
Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response to neoadjuvant therapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence, to continue with the chemotherapy± radiotherapy is often used in these cases. However, the overall survival is still poor. We designed a prospective randomized controlled tial to study whether immunotherapy could be used with chemotherapy after surgery to improve overall survival. The primary endpoint ofthe study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life.
Eligibility
Inclusion Criteria:
Histologically proven esophageal or EG-junction carcinoma (Siewert I-II). The heart and
lung function can tolerate surgery. The cancer is resectable and incurable therapy will be
perfomed.
Exclusion Criteria:
EG-junction carcinoma (Siewert III). M1 stage according to the current (8th) version of
TNMclassification system. The heart and lung function can't tolerate surgery. R2 Resection
Status.